Lymphoblastic Leukemia, Acute, Childhood Clinical Trial
Official title:
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730
This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
The phase 1 study is to determine the maximum tolerated dose (MTD) of the PO formulation, followed by a screening phase 2 study to investigate the efficacy of ixazomib in combination with chemotherapy in children with relapsed ALL and lymphoblastic lymphoma (LLy). The single arm, screening phase 2 design will allow us to use a minimal number of patients to obtain preliminary information about treatment efficacy. Discovering a safe and tolerable dose of ixazomib in a PO formulation and the preliminary efficacy data will significantly increase the possibility of ixazomib moving forward in frontline pediatric treatment protocols in both intense chemotherapy courses and maintenance courses. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05043571 -
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
|
Phase 1 | |
| Recruiting |
NCT05495035 -
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
|
Phase 1 | |
| Completed |
NCT01411267 -
AC220 for Children With Relapsed/Refractory ALL or AML
|
Phase 1 | |
| Completed |
NCT00991133 -
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
|
Phase 1 | |
| Active, not recruiting |
NCT05440409 -
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
|
||
| Completed |
NCT01861002 -
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
|
Phase 1 | |
| Terminated |
NCT01100658 -
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
|
N/A | |
| Completed |
NCT01321346 -
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT01896752 -
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL
|
N/A | |
| Completed |
NCT01614197 -
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05429905 -
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02879643 -
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
|
Phase 1 | |
| Recruiting |
NCT03022747 -
Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol
|
Phase 2 | |
| Terminated |
NCT05611086 -
N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia
|
Phase 4 | |
| Terminated |
NCT01186328 -
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
|
Phase 1 | |
| Completed |
NCT02906371 -
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
|
Phase 1 | |
| Recruiting |
NCT05038696 -
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
|
Phase 1 |